Site icon pharmaceutical daily

Irritable Bowel Syndrome (IBS) Pipeline Monitor 2020 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Irritable Bowel Syndrome Pipeline Research Monitor, 2020 – Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook” report has been added to ResearchAndMarkets.com’s offering.

PIPELINE HIGHLIGHTS

Irritable Bowel Syndrome is one of the widely researched conditions during 2020 with 34 companies actively focusing on realizing pipeline’s potential. Development of Irritable Bowel Syndrome medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Irritable Bowel Syndrome market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Irritable Bowel Syndrome.

Good progress is anticipated during 2020 and 2021 with Irritable Bowel Syndrome pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Irritable Bowel Syndrome pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

DRUG DEVELOPMENT PIPELINE OVERVIEW

The Irritable Bowel Syndrome pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Irritable Bowel Syndrome pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Irritable Bowel Syndrome presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Irritable Bowel Syndrome pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report. (Read more…)

DRUG PROFILES

Irritable Bowel Syndrome development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided:

COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Irritable Bowel Syndrome drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Irritable Bowel Syndrome. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 34 Irritable Bowel Syndrome companies including company overview, key snapshot, contact information, and their strategies on accelerating Irritable Bowel Syndrome pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Reasons to Buy

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/6dz2dx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version